TORONTO and HAIFA, Israel, May 02, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is deepening its engagement with the European financial and healthcare communities through participation in three
Amid an ongoing war and the departure of thousands of high-tech workers, Israeli tech companies are grappling with the question of where they should operate from — within Israel or overseas. Four CEOs managing companies with global clients and teams share their choices with mako, talk about life split between Israel
חברת הביוטק הישראלית NurExone פיתחה טכנולוגיה מהפכנית לטיפול באנשים עם פגיעות במערכת העצבים המרכזית, שנחשבו עד היום לבלתי הפיכות. הטכנולוגיה, שמבוססת על ננו-חלקיקים טבעיים, מצליחה לעשות את הבלתי יאמן ולהביא לחידוש של תאי עצב פגועים ולשיקום פונקציונלי. זו בשורה חשובה גם לנפגעי המלחמה Raed More >>>
TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries is presenting new data at the 2025 International Society for Extracellular Vesicles (ISEV) Annual Meeting
We are pleased to announce the appointment of Jacob Licht as Chief Executive Officer of Exo-Top Inc. (“Exo-Top”), a wholly owned subsidiary of the Company, and as Vice President, Corporate Development at NurExone. Exo-Top is a U.S.-based GMP-compliant exosome manufacturing site and will be the pillar of the Company’s global
TORONTO and HAIFA, Israel, April 10, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2024. The Company’s audited consolidated financial
TORONTO and HAIFA, Israel, April 04, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, Germany: J90) (“NurExone” or the “Company”) is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 3,543,238 units (“Units”) at a price of C$0.65 per
